Cardiometabolic Therapeutics · Rare Disease Therapeutics
Alnylam revenue, results and funding
Alnylam filed revenue of $3.7B for 2025.
Data updated Nov 15, 2026 · Back to the company report
$3.7BRevenue, 2025
$313.7MNet income, 2025
115Employees, 2011
Results by year
| Year | Revenue | Net income | Total assets | Employees |
|---|---|---|---|---|
| 2025 | $3.7B | $313.7M | $5B | – |
| 2024 | $2.2B | −$278.2M | $4.2B | – |
| 2023 | $1.8B | −$440.2M | $3.8B | – |
| 2022 | $1B | −$1.1B | $3.5B | – |
| 2021 | $844.3M | −$852.8M | $3.6B | – |
| 2020 | $492.9M | −$858.3M | $3.4B | – |
| 2019 | $219.8M | −$886.1M | $2.4B | – |
| 2018 | $74.9M | −$761.5M | $1.6B | – |
| 2017 | $89.9M | −$490.9M | $2B | – |
| 2016 | $47.2M | −$410.1M | $1.3B | – |
| 2015 | – | −$290.1M | $1.4B | – |
| 2014 | – | −$360.4M | $1.1B | – |
| 2013 | – | −$89.2M | $420.5M | – |
| 2012 | – | −$106M | $287.5M | – |
| 2011 | – | −$57.6M | $281.9M | 115 |
Sources: SEC
How to cite
Alnylam, Financials. Alion, Nov 15, 2026. https://alion.io/company/alnylam/financials